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Technologies are an important driver of progress in the
medical sciences. Recent advances in array-based and
sequence-based instrumentation have opened up new ways
to monitor the inner molecular world of the cells and
tissues that might be relevant to human diseases. Yet it is far
from evident how these large datasets should be analyzed
and how they can be integrated with other sources of data
in order to become informative. Conversely, the medical
community expects nothing less than a list of predictive
biomarkers reflecting the risk of disease or its progression
and an understanding of the cellular mechanisms involved
in disease. However, comparing microarray samples from
healthy and diseased individuals using a differential gene
expression protocol generates a list of thousands of genes,
and it is not clear which genes are important for what.
A key idea, originating from engineering science in general
and computer science in particular, is the notion of ‘divide
and conquer’, which refers to first breaking down a problem
into smaller sub-problems that are simple enough to allow
an analysis and then combining the solutions to the sub-
problems, which gives the solution to the original problem.
Modular analysis of genomic data implements this strategy
by dividing the original genomic data into smaller number
of modules and then conquering the reduced complexity by
using these modules for prioritization to give a shorter list
of disease-associated genes. Such genes could either be
causal drivers of disease or secondary reactions to disease
that could potentially be useful biomarkers.
Benson and colleagues, in a recent paper in BMC Systems
Biology [1], have used a modular approach to study allergic
asthma. They managed to divide the complexity and arrive
at the gene encoding the interleukin-7 receptor (IL7R) as a
putative key regulator in allergic asthma. Importantly, their
computational analysis is accompanied by experiments.
Here, I put their analysis in the context of other modular
approaches and discuss the possible use of this
methodology for finding and prioritizing useful candidates
for therapeutics.
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Not surprisingly, there are several different ideas on how to
divide and conquer high-throughput functional genomics
data. I will restrict my discussion here to gene expression
data, although similar remarks could be made for sequence
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Complex diseases such as allergy change gene expression in several cell types and tissues. Benson
and colleagues have now shown, in a paper in BMC Systems Biology, that this complexity can be
studied effectively using an integrated experimental and computational modular analysis. Their
strategy revealed a core of allergy-associated genes of potential therapeutic value.
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given a module of disease-associated genes, how can we
compute and/or experimentally predict which genes are good
candidates for therapeutics? Before discussing this problem I
will first give an overview of different approaches to the other
problem: identifying a module of genes.
A module is a group of genes that are related in some way to
each other and therefore a module is effectively a measure
of similarity. Grouping genes into modules depends on an
exact mathematical definition of similarity. For example, if
similarity is defined as the distance in a network, then a
graph theoretical calculation will be used. However, if gene
functional associations are used, then gene similarity will be
measured in terms of gene ontology (GO) or correlation in
gene expression values. Therefore, different algorithms are
used for dividing the genes into modules, a fact that could
be confusing for the clinical researcher.
The need to reduce the complexity of the original high-
throughput gene expression data was realized early on in its
analysis [2]. Applying established engineering concepts,
such as principal component analysis (PCA) and singular
value decomposition (SVD), reduced the dimensionality of
the data. Instead of analyzing scattered points (the samples)
in a high-dimensional space equaling the number of genes,
the data could thereby be projected into a two- to four-
dimensional space. However, it turned out to be difficult to
make a biological interpretation of the resulting linear
combinations of large numbers of genes. This problem
forced the development of different strategies in which the
available knowledge on a limited number of genes could be
used to predict the functions of as-yet uncharacterized genes.
The use of hierarchical clustering in the classic compendium
study on yeast data by Rosetta Inpharmatics [3] grouped
genes (shown as rows) by their similarity of expression
across several experimental conditions (columns). Novel
gene function was then predicted by inspecting genes in the
same cluster as genes with known functions. Subsequent
work by Eran Segal and colleagues [4] developed more
statistically sound procedures for identifying robust modules
using a Bayesian formalism applied to microarray data
generated from cancer samples.
It became clear, however, that a similarity measure based
only on correlations was insufficient, because the clusters
(modules) or Bayesian modules did not have an internal
network structure that could be used for a more refined
analysis. As a consequence, a large number of studies
addressing this problem appeared in the literature at the
beginning of 2004. The idea was that if we could identify
the wiring within cellular networks, various different
algorithms could be applied to find ‘connected groups’ in
such networks. Such an analysis would then provide more
biological insights into the mechanisms of disease.
Now, how can such networks be found using only a small
number of experimental samples with a large number of
genes? This is an impossible problem from the point of
view of engineering system identification, because the
number of possible networks consistent with the data is
prohibitively large [5]. The key simplifying insight came
from Ideker and Lauffenburger [6] and was later developed
by Nicolas Luscombe and colleagues in a pioneering paper
[7]. Here, the edges (or connections) in the network were
simply defined by transcription factor binding experiments,
and gene expression data were used to select the subsets of
edges that were active under different conditions.
This idea of defining edges in a network using a static
scaffold has since been reused using various data types
(protein-protein interaction data, pathways from a
database, text mining and DNA variants). The network of
interest is then defined by combining the gene expression
data with the scaffold, leaving only the active edges. By
searching through such an active network using graph
algorithms it is then possible to define ‘more’ connected
parts in a well defined manner, thereby providing modules
with an intrinsic network structure.
All the above approaches basically begin with a large,
complex dataset, which is then simplified by dividing the
data into smaller modules. Interestingly, Vidal and colleagues
[8] demonstrated that this process can be reversed. They
instead began with four well characterized breast cancer
genes and, by using these ideas, constructed a module in
which the genes were ‘close’ as defined by expression and
proteomic data in several species.
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Benson and colleagues [1] have now contributed to a
disease-oriented modular analysis by combining several of
the above ideas in a novel manner, as summarized in the
flow chart in Figure 1. First, because allergic disease involves
multiple cells in different tissues and because no prior
characterization of key genes was available, they turned to
several different sets of gene expression microarray data in
order to find a reference disease-associated gene around
which they could construct a module. Using the idea that
disease-associated genes tend to interact, they could search
for other disease-associated genes that were ‘close’. For this
purpose, the authors used a graph algorithm that identified
a connected clique of 103 disease-associated genes from the
microarray data.
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pathway shared by these 103 genes, as detected by the
Ingenuity Pathway Analysis tool, which identifies physical,
transcriptional and enzymatic interactions from the litera-
ture [1]. Experimental analysis of this pathway in patient-
derived cells revealed strong activation of the ITK gene,
which is also known to be located in the genomic suscepti-
bility region for allergy. Combining a promoter analysis of
the ITK gene with expression data revealed that the trans-
cription factor GATA3 regulated ITK.
Finally, using available databases, 47 genes were identified
as interacting with GATA3. The expression data were used to
filter out 10 inactive genes, thus leaving a final module of
37 disease-associated genes around the GATA3 transcription
factor [1]. The construction of this module was accompa-
nied by several experimental tests at various stages, provid-
ing confidence to the analysis.
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The problem of selecting therapeutic targets within a
module has not received much attention in studies that
have used a modular approach for reducing complexity.
There are various ideas from graph theory on how to
compute mathematically defined properties, such as
clustering and connectivity in large networks, which then
could suggest which nodes are essential. However,
essentiality is not necessarily equivalent to disease
association. Experimental investigators have instead
performed target selection using the full dataset in
combination with extensive experimental testing. This is, by
most measures, an inefficient and expensive procedure.
The analysis by Benson and colleagues [1] is important
because it highlights the difficulty of selecting a disease-
associated target from a module of 37 genes despite the
elegant prior reduction of complexity. They resorted to
using a connectivity criterion, selecting the IL7R gene
because it had the largest number of connections, and they
were also able to demonstrate that perturbing the IL7R gene
affected other genes and the T-cell phenotype. There are
probably several other disease-associated genes in their
module that warrant further experimental investigation.
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Benson and colleagues [1] have introduced a useful procedure
for defining a module of disease-associated genes. As with
most complex diseases, the study of allergy is complicated
by the fact that the disease affects several cell types and
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Flowchart of the modular analysis by Benson and colleagues [1]. Integration of several public gene expression datasets revealed a group of shared
(blue) and closely connected clique (red and black) disease-associated genes. A subset of these genes were found to share the T-cell receptor
signalling pathway, an observation that was then validated by independent experimentation. To identify a transcription factor (GATA3) regulating one
of this subset, the ITK gene, a promoter analysis was performed. The final module of 37 disease-associated genes consisted of genes listed in public
databases as having relevant expression patterns and interacting with GATA3.
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Interactionstissues. The process of identifying such modules therefore
requires the kind of stringent experimental validation as was
performed by the Benson team [1]. Despite their careful
analysis, because there are other transcription factors for the
ITK gene that are active in the expression datasets there is a
significant risk that several disease-associated genes remain
that were not captured in their module.
The second step of selecting a gene for therapeutics from a
module is even more problematic because we are currently
lacking systematic tools for this selection problem. Further-
more, it is not unlikely that an efficient therapy could require
targeting of several disease-associated genes simultaneously.
However, the number of combinations of three genes that
can be chosen from a small ten-gene module, for example,
quickly exceeds what is experimentally feasible to study.
In conclusion, Benson and colleagues [1] have devised an
interesting method for finding disease-associated genes, but
it needs to be evaluated on other complex diseases. Their
study also makes clear that the problem of prioritizing
disease-associated genes within a module for therapeutic
studies in the clinic is still unsolved.
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